Audit of the management of patients admitted with community acquired pneumonia

Irish Medical Journal

Volumn 99, Issue 5, 2006, Pages

  Foley, Susan C ^a   Kelly, Emer ^b   O'Neill, S J ^b  

^a MCGILL UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; LEVOFLOXACIN; VACCINE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; EMERGENCY WARD; EMPYEMA; HEALTH CARE QUALITY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL AUDIT; MEDICAL RECORD; MORTALITY; PATIENT REFERRAL; PLEURA EFFUSION; PRACTICE GUIDELINE; PRESCRIPTION; PROSPECTIVE STUDY; SMOKING CESSATION; WINTER;

EID: 33747680987     PISSN: 03323102     EISSN: 03323102     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Woodhead MA, Macfarlane JT, McCracken JS, Rose DH, Finch RG. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987Mar;1(8534): 671-4.
2. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the United Kingdom. Eur Respir J 1997 Jul; 10(7): 1530-4.
3. British Thoracic Society Research Committee and Public Health Laboratory Service.The aetiology, management and outcome of severe community-acquired pneumonia on the intensive care unit. Respir Med 1992; 86: 7-13.
4. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E et al. Severe community acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991 Aug;144(2): 312-8.
5. B.T.S. Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001;56(Suppl 4): iv1-iv64.
6. Gleason PP, Kapoor WN, Stone RA, Lave JR, Obrosky DS, Schulz R et al. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia. JAMA 1997; 278: 32-39.
7. Gilbert K, Gleason PP, Singer DE, Marrie TJ, Coley CM, Obrosky DS et al. Variations in antimicrobial use and cost in more than 2,000 patients with community-acquired pneumonia. Am J Med 1998 Jan;104(1): 17-27.
8. Lim WS, Macfarlane JT, Boswell TC, Harrison TG, Rose D, Leinonen M et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001 Apr; 56: 296-301.
9. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278 (23): 2080-4.
10. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and Cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med l994; 331(12): 778-84.
11. Fedson DS, Wajda A, Nicol JP, Hammond GW, Kaiser DL, Roos LL. Clinical effectiveness of influenza vaccination in Manitoba. JAMA 1993; 270(16): 1956-61.
12. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136 (3): 296-307.
13. Nichol KL. Complications of influenza and benefits of vaccination. Vaccine 1999 Jul;17:Suppl 1:S47-52.
14. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med 1999 Mar;130(5):397-403.
15. Fine MJ, Smith MA, Carson CA, Meffe F, Sankey SS, Weissfeld LA et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis of randomized controlled trials. Arch Intern Med 1994 Dec;154(23):2666-77.